Pharmaceuticals, Biotechnology and Life Sciences
– COSMIC-313 is the third phase 3 pivotal trial to investigate cabozantinib in combination with immune checkpoint inhibitors – ALAMEDA,…
– Total Revenue of $215.5 Million, Cabozantinib Franchise Revenue of $179.6 Million – – GAAP Diluted EPS of $0.24, Non-GAAP…
Conference Call Scheduled for Today, May 1, 2019, at 3:30 PM CT (4:30 PM ET) Revenues of $63.3 million increased…
PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule…
Updates Fiscal 2019 Guidance EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro…
CHICAGO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/ChevronPouches?src=hash" target="_blank"gt;#ChevronPoucheslt;/agt;–Exhibiting its latest developments in medical materials capabilities at CPhI North America, flexible packaging leader ProAmpac today…
JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Letairis®1 (ambrisentan)…
DENVER–(BUSINESS WIRE)–Having recently been named to the Top 10 eClinical Companies for 2019 by Pharma Tech Outlook Magazine, ClinOne brings…
DUBLIN–(BUSINESS WIRE)–The “Patient Recruitment and Retention Services Market, 2019-2030” report has been added to ResearchAndMarkets.com’s offering. Patient Recruitment and Retention…
BOSTON–(BUSINESS WIRE)–Outcome Capital, a specialized investment banking firm that serves middle market growth companies in the life science and technology…